doi : 10.1016/S1936-8798(21)00975-4
Volume 14, Issue 12, 28 June 2021, Pages A12-A16
Dean J.KereiakesMDaRenuVirmaniMDbJason Y.HokamaPhDcUdayIllindalaPhDcCarlosMena-HurtadoMDdAndrewHoldenMDeJonathan M.HillMDfSean P.LydenMDgZiad A.AliMD, DPhilh
doi : 10.1016/j.jcin.2021.03.036
Volume 14, Issue 12, 28 June 2021, Pages 1275-1292
A significant proportion of lesions treated with transcatheter interventions in the coronary and peripheral vascular beds exhibit moderate to severe calcific plaques known to portend lower procedural success rates, increased peri-procedural adverse events, and unfavorable clinical outcomes compared with noncalcific plaques. Adapted from lithotripsy technology used for treatment of ureterorenal calculi, intravascular lithotripsy (IVL) is a novel technique for the treatment of severely calcific plaque lesions that uses acoustic shockwaves in a balloon-based delivery system. Shockwaves induce calcium fractures, which facilitate stent expansion and luminal gain. In this review, the authors summarize the physics, preclinical and clinical data on IVL use in the coronary and peripheral vasculature, and future directions of IVL in transcatheter cardiovascular therapies.
Thomas A.MeijersMDaAdelAminianMDbMarleenvan WelyMDcKoenTeeuwenMD, PhDdThomasSchmitzMDeMaurits T.DirksenMD, PhDfSudhirRathoreMDgRené J.van der SchaafMD, PhDhPaulKnaapenMD, PhDiJosephDensMD, PhDjJuan F.IglesiasMDkPierfrancescoAgostoniMD, PhDlVincentRoolvinkMD, PhDaRenicus S.HermanidesMD, PhDaNielsvan RoyenMD, PhDcMaarten A.H.van LeeuwenMD, PhDa
doi : 10.1016/j.jcin.2021.03.041
Volume 14, Issue 12, 28 June 2021, Pages 1293-1303
The aim of this study was to investigate whether transradial (TR) percutaneous coronary intervention (PCI) is superior to transfemoral (TF) PCI in complex coronary lesions with large-bore guiding catheters with respect to clinically relevant access site–related bleeding or vascular complications.
MarcoValgimigliMD, PhDabAntonioLandiMDa
doi : 10.1016/j.jcin.2021.04.013
Volume 14, Issue 12, 28 June 2021, Pages 1304-1307
EvangeliaVemmouMDaAlexandre S.QuadrosMD, PhDbJoseph A.DensMD, PhDcNidal AbiRafehMDdPierfrancescoAgostoniMD, PhDeKhaldoonAlaswadMDfAlexandreAvranMD, MScgKarlyse C.BelliPhDbMauroCarlinoMDhJames W.ChoiMDiAhmedEl-GuindyMD, MScjFarouc A.JafferMD, PhDkDimitriKarmpaliotisMD, PhDlJaikirshan J.KhatriMDmDmitriiKhelimskiiMDnPaulKnaapenMD, PhDoAlessioLa MannaMDpOlegKrestyaninovMDnPabloLamelasMD, MScqSoledadOjedaMD, PhDrLucioPadillaMDqManuelPanMD, PhDrPedroPiccaro de OliveiraMD, PhDsStéphaneRinfretMD, SMtJames C.SprattMDuMasakiTanabeMDvSimonWalshMDwIliasNikolakopoulosMDaJuditKaracsonyiMD, PhDaBavana V.RanganBDS, MPHaEmmanouil S.BrilakisMD, PhDaLorenzoAzzaliniMD, PhD, MScx
doi : 10.1016/j.jcin.2021.04.003
Volume 14, Issue 12, 28 June 2021, Pages 1308-1319
The authors sought to examine the outcomes of percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) chronic total occlusions (CTOs).
ZiyadGhazzalMDFadiSawayaMD
doi : 10.1016/j.jcin.2021.04.017
Volume 14, Issue 12, 28 June 2021, Pages 1320-1322
Rosanne F.VogelMDaRonakDelewiMD, PhDbDominick J.AngiolilloMD, PhDcJeroen M.WilschutMDdMiguel E.LemmertMD, PhDdeRobertoDilettiMD, PhDdRiavan VlietfNancy W.P.L.van der WaardenMScgRutger-JanNuisMD, PhDdValeriaParadiesMDfDimitriosAlexopoulosMD, PhDhFelixZijlstraMD, PhDdGillesMontalescotMD, PhDiMitchell W.KrucoffMD, PhDjNicolas M.van MieghemMD, PhDdPieter C.SmitsMD, PhDfGeorgios J.VlachojannisMD, PhDaf
doi : 10.1016/j.jcin.2021.04.022
Volume 14, Issue 12, 28 June 2021, Pages 1323-1333
This study sought to compare the pharmacodynamic effects of pre-hospitally administered P2Y12 inhibitor prasugrel in crushed versus integral tablet formulation in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).
ArkaChatterjeeMDKristinaSkinnerDO
doi : 10.1016/j.jcin.2021.05.001
Volume 14, Issue 12, 28 June 2021, Pages 1334-1336
Dean J.KereiakesMDaCarloDi MarioMDbRobert F.RileyMDaJeanFajadetMDcRichard A.ShlofmitzMDdShigeruSaitoMDeZiad A.AliMD, DPhildfAndrew J.KleinMDgMatthew J.PriceMDhJonathan M.HillMDiGregg W.StoneMDj
doi : 10.1016/j.jcin.2021.04.015
Volume 14, Issue 12, 28 June 2021, Pages 1337-1348
The aim of this pooled analysis was to assess the cumulative safety and effectiveness of coronary intravascular lithotripsy (IVL).
Ajay J.KirtaneMDMatthew T.FinnMD
doi : 10.1016/j.jcin.2021.05.008
Volume 14, Issue 12, 28 June 2021, Pages 1349-1351
GunnarTepeMDaMarianneBrodmannMDbMartinWernerMDcWilliamBachinskyMDdAndrewHoldenMDeThomasZellerMDfSarangMangalmurtiMDgClausNolte-ErnstingMDhBarryBertoletMDiDierkScheinertMD, PhDjWilliam A.GrayMDkDisrupt PAD III Investigators
doi : 10.1016/j.jcin.2021.04.010
Volume 14, Issue 12, 28 June 2021, Pages 1352-1361
The study sought to compare short-term outcomes in patients with femoropopliteal artery calcification receiving vessel preparation with intravascular lithotripsy (IVL) or percutaneous transluminal angioplasty (PTA) prior to drug-coated balloon (DCB) for symptomatic peripheral artery disease.
Christopher J.WhiteMDabJoshua A.BeckmanMDc
doi : 10.1016/j.jcin.2021.04.025
Volume 14, Issue 12, 28 June 2021, Pages 1362-1363
Efthymios D.AvgerinosMDaWissamJaberMDbJoanLacomisMDcKyleMarkelMDaMichaelMcDanielMDbBelinda N.Rivera-LebronMDdCharles B.RossMDeJacobSechristMDcCatalinTomaMDfRabihChaerMDa
doi : 10.1016/j.jcin.2021.04.049
Volume 14, Issue 12, 28 June 2021, Pages 1364-1373
The aim of this trial was to determine whether ultrasound-assisted thrombolysis (USAT) is superior to standard catheter-directed thrombolysis (SCDT) in pulmonary arterial thrombus reduction for patients with submassive pulmonary embolism (sPE).
Akhilesh K.SistaMD
doi : 10.1016/j.jcin.2021.05.020
Volume 14, Issue 12, 28 June 2021, Pages 1374-1375
DejanMilasinovicMDabMilojeTomasevicMD, PhDacVladanVukcevicMD, PhDabGoranStankovicMD, PhDab
doi : 10.1016/j.jcin.2021.03.016
Volume 14, Issue 12, 28 June 2021, Pages 1376-1377
YujiKiyoseaTatsuyaShirakiMDbIsamuMizoteMD, PhDbDaisukeNakamuraMDbYasumasaTsukamotoMD, PhDbKensukeYokoiMDbHidetakaKiokaMD, PhDbTomohitoOhtaniMD, PhDbShungoHikosoMD, PhDbShigeruMinamiPhDaYasushiSakataMD, PhDb
doi : 10.1016/j.jcin.2021.03.042
Volume 14, Issue 12, 28 June 2021, Pages 1378-1380
Madeline K.MahowaldMDMichel T.CorbanMDMackram F.EleidMDRick A.NishimuraMD
doi : 10.1016/j.jcin.2021.04.018
Volume 14, Issue 12, 28 June 2021, Pages e129-e130
HiroyukiGiboMDaShotaSaitoMDaJiroKoyaMDaYutaroYasuiMDaYusukeTokudaMD, PhDaKazuyaSugitatsuMDaYasuhiroMakitaMDaKazuharuSuzukiMDbShuichiMiyamotoMDbMorioShodaMD, PhDcd
doi : 10.1016/j.jcin.2021.03.044
Volume 14, Issue 12, 28 June 2021, Pages e131-e133
FélixDamas de los SantosMDaJulio I.Farjat PasosMDaKathia E.Estrada LopezMDaRam?n J.Cue CarpioMDbEduardo A.AriasMDa
doi : 10.1016/j.jcin.2021.03.017
Volume 14, Issue 12, 28 June 2021, Pages e135-e138
SripalBangaloreMD, MHAAhmadAlkhalilMDFrederickFeitMDNormaKellerMDCraigThompsonMD
doi : 10.1016/j.jcin.2021.03.067
Volume 14, Issue 12, 28 June 2021, Pages e139-e141
Alexandra E.TengMDaJosephYangMDabJeffrey M.ZimmetMD, PhDabKendrick A.ShunkMD, PhDab
doi : 10.1016/j.jcin.2021.03.068
Volume 14, Issue 12, 28 June 2021, Pages e143-e145
Juan G.C?rdoba-SorianoMDJuan JoséPortero-PortazMDArsenioGallardo-L?pezMDAntonioGutiérrez-D?ezMDDrissMelehiMD, PhDJes?sJiménez-MazuecosMD
doi : 10.1016/j.jcin.2021.04.027
Volume 14, Issue 12, 28 June 2021, Pages 1381-1382
DimitriosVenetsanosMD, PhDMikolajSkibniewskiMDJoakimAlfredssonMD, PhD
doi : 10.1016/j.jcin.2021.05.009
Volume 14, Issue 12, 28 June 2021, Page 1382
JaytinGuptaMSHector M.Garcia-GarciaMD, PhD
doi : 10.1016/j.jcin.2021.04.029
Volume 14, Issue 12, 28 June 2021, Page 1383
ShilpkumarAroraMPH, MDRahulJaswaneyMDMehdi H.ShishehborDO, MPH, PhD
doi : 10.1016/j.jcin.2021.05.003
Volume 14, Issue 12, 28 June 2021, Pages 1383-1384
MarcoZuinMDGianlucaRigatelliMD, PhDGiovanniZulianiMD, PhDLorisRonconMD
doi : 10.1016/j.jcin.2021.04.039
Volume 14, Issue 12, 28 June 2021, Pages 1384-1385
Akhilesh K.SistaMDJames M.HorowitzMDVictor F.TapsonMDJames F.BenenatiMD
doi : 10.1016/j.jcin.2021.05.018
Volume 14, Issue 12, 28 June 2021, Pages 1385-1386
Neel M.ButalaMD, MBAKamil F.FaridiMDEric A.SecemskyMD, MScYangSongMSJepthaCurtisMDC. MichaelGibsonMD, MSRalphBrindisMD, MPHChangyuShenPhDRobert W.YehMD, MSc
doi : 10.1016/j.jcin.2021.03.065
Volume 14, Issue 12, 28 June 2021, Pages 1386-1388
William F.FearonMD†CarlosColletMD, PhD†BrunoRoza da CostaPhDTakuyaMizukamiMD, PhDEmanueleBarbatoMD, PhDPim A.L.ToninoMD, PhDNico H.J.PijlsMD, PhDPeterJüniMD‡BernardDe BruyneMD, PhD‡
doi : 10.1016/j.jcin.2021.04.021
Volume 14, Issue 12, 28 June 2021, Pages 1388-1390
JosefVeselkaMD, PhDLotharFaberMD, PhDMaxLiebregtsMD, PhDRobertCooperMBChB, MRCPMaksimKashtanovMD, PhDPeter RiisHansenMD, DMSc, PhDJiriBonaventuraMDEvaPolakovaMDEvaHansvenclovaHenningBundgaardMD, DMScJurriënten BergMD, PhDMorten KvistholmJensenMD, PhD
doi : 10.1016/j.jcin.2021.03.066
Volume 14, Issue 12, 28 June 2021, Pages 1390-1392
Do you want to add Medilib to your home screen?